Do analysts rate ESLA or TLSA?

Estrella Immunopharma currently has a consensus price target of $8.00, indicating a potential upside of 595.65%. Given Estrella Immunopharma's stronger consensus rating and higher possible upside, analysts plainly believe Estrella Immunopharma is more favorable than Tiziana Life Sciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Estrella Immunopharma 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Tiziana Life Sciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, ESLA or TLSA?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Estrella Immunopharma N/A N/A -$13.06M -$0.34 N/A Tiziana Life Sciences N/A N/A -$18.43M N/A N/A

Is ESLA or TLSA more profitable?

Company Net Margins Return on Equity Return on Assets Estrella Immunopharma N/A N/A -397.36% Tiziana Life Sciences N/A N/A N/A

Does the media refer more to ESLA or TLSA?

In the previous week, Estrella Immunopharma and Estrella Immunopharma both had 1 articles in the media. Estrella Immunopharma's average media sentiment score of 0.87 beat Tiziana Life Sciences' score of 0.63 indicating that Estrella Immunopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Estrella Immunopharma 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Tiziana Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ARTV or ESLA more profitable?

Estrella Immunopharma's return on equity of 0.00% beat Artiva Biotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Artiva Biotherapeutics N/A -73.15% -62.74% Estrella Immunopharma N/A N/A -397.36%

Is RNAC or ESLA more profitable?

Estrella Immunopharma has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -8,550.65%. Company Net Margins Return on Equity Return on Assets Cartesian Therapeutics -8,550.65% N/A -28.25% Estrella Immunopharma N/A N/A -397.36%

Does the media prefer RNAC or ESLA?

In the previous week, Cartesian Therapeutics and Cartesian Therapeutics both had 1 articles in the media. Estrella Immunopharma's average media sentiment score of 0.87 beat Cartesian Therapeutics' score of 0.62 indicating that Estrella Immunopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cartesian Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Estrella Immunopharma 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate ESLA or JMAC?

Estrella Immunopharma presently has a consensus target price of $8.00, suggesting a potential upside of 595.65%. Given Estrella Immunopharma's stronger consensus rating and higher probable upside, research analysts plainly believe Estrella Immunopharma is more favorable than Maxpro Capital Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Estrella Immunopharma 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Maxpro Capital Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings & valuation, ESLA or JMAC?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Estrella Immunopharma N/A N/A -$13.06M -$0.34 N/A Maxpro Capital Acquisition N/A N/A N/A N/A N/A

Is ESLA or JMAC more profitable?

Company Net Margins Return on Equity Return on Assets Estrella Immunopharma N/A N/A -397.36% Maxpro Capital Acquisition N/A N/A N/A

Estrella Immunopharma (ESLA) Competitors

$1.15 +0.11 (+10.58%)

As of 02:44 PM Eastern

Compare

ESLA vs. DTIL, TLSA, ARTV, RNAC, and JMAC

Should you buy Estrella Immunopharma stock or one of its competitors? MarketBeat compares Estrella Immunopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Estrella Immunopharma include Precision BioSciences (DTIL), Tiziana Life Sciences (TLSA), Artiva Biotherapeutics (ARTV), Cartesian Therapeutics (RNAC), and Maxpro Capital Acquisition (JMAC). These companies are all part of the "pharmaceutical products" industry.

How does Estrella Immunopharma compare to Precision BioSciences?

Precision BioSciences (NASDAQ:DTIL) and Estrella Immunopharma (NASDAQ:ESLA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations, profitability and media sentiment.

Estrella Immunopharma has lower revenue, but higher earnings than Precision BioSciences. Estrella Immunopharma is trading at a lower price-to-earnings ratio than Precision BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precision BioSciences	$34.26M	4.81	-$45.72M	-$3.67	N/A
Estrella Immunopharma	N/A	N/A	-$13.06M	-$0.34	N/A

Precision BioSciences has a beta of 1.3, suggesting that its share price is 30% more volatile than the broader market. Comparatively, Estrella Immunopharma has a beta of 0.85, suggesting that its share price is 15% less volatile than the broader market.

38.0% of Precision BioSciences shares are owned by institutional investors. Comparatively, 0.4% of Estrella Immunopharma shares are owned by institutional investors. 2.7% of Precision BioSciences shares are owned by insiders. Comparatively, 5.8% of Estrella Immunopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Precision BioSciences presently has a consensus target price of $36.33, suggesting a potential upside of 468.69%. Estrella Immunopharma has a consensus target price of $8.00, suggesting a potential upside of 595.65%. Given Estrella Immunopharma's higher possible upside, analysts plainly believe Estrella Immunopharma is more favorable than Precision BioSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precision BioSciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Estrella Immunopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Estrella Immunopharma had 1 more articles in the media than Precision BioSciences. MarketBeat recorded 1 mentions for Estrella Immunopharma and 0 mentions for Precision BioSciences. Estrella Immunopharma's average media sentiment score of 0.87 beat Precision BioSciences' score of 0.63 indicating that Estrella Immunopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Precision BioSciences	Positive
Estrella Immunopharma	Positive

Estrella Immunopharma has a net margin of 0.00% compared to Precision BioSciences' net margin of -96.73%. Estrella Immunopharma's return on equity of 0.00% beat Precision BioSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precision BioSciences	-96.73%	-85.37%	-37.34%
Estrella Immunopharma	N/A	N/A	-397.36%

Summary

Estrella Immunopharma beats Precision BioSciences on 8 of the 15 factors compared between the two stocks.

How does Estrella Immunopharma compare to Tiziana Life Sciences?

Estrella Immunopharma (NASDAQ:ESLA) and Tiziana Life Sciences (NASDAQ:TLSA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and media sentiment.

Estrella Immunopharma currently has a consensus price target of $8.00, indicating a potential upside of 595.65%. Given Estrella Immunopharma's stronger consensus rating and higher possible upside, analysts plainly believe Estrella Immunopharma is more favorable than Tiziana Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Estrella Immunopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Tiziana Life Sciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Estrella Immunopharma has a beta of 0.85, indicating that its share price is 15% less volatile than the broader market. Comparatively, Tiziana Life Sciences has a beta of 0.44, indicating that its share price is 56% less volatile than the broader market.

0.4% of Estrella Immunopharma shares are owned by institutional investors. 5.8% of Estrella Immunopharma shares are owned by company insiders. Comparatively, 39.8% of Tiziana Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Estrella Immunopharma and Estrella Immunopharma both had 1 articles in the media. Estrella Immunopharma's average media sentiment score of 0.87 beat Tiziana Life Sciences' score of 0.63 indicating that Estrella Immunopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Estrella Immunopharma	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Tiziana Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Net Margins	Return on Equity	Return on Assets
Estrella Immunopharma	N/A	N/A	-397.36%
Tiziana Life Sciences	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Estrella Immunopharma	N/A	N/A	-$13.06M	-$0.34	N/A
Tiziana Life Sciences	N/A	N/A	-$18.43M	N/A	N/A

Summary

Estrella Immunopharma beats Tiziana Life Sciences on 7 of the 9 factors compared between the two stocks.

How does Estrella Immunopharma compare to Artiva Biotherapeutics?

Artiva Biotherapeutics (NASDAQ:ARTV) and Estrella Immunopharma (NASDAQ:ESLA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

Artiva Biotherapeutics currently has a consensus price target of $39.00, indicating a potential upside of 427.67%. Estrella Immunopharma has a consensus price target of $8.00, indicating a potential upside of 595.65%. Given Estrella Immunopharma's higher possible upside, analysts clearly believe Estrella Immunopharma is more favorable than Artiva Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artiva Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Estrella Immunopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

0.4% of Estrella Immunopharma shares are owned by institutional investors. 21.4% of Artiva Biotherapeutics shares are owned by insiders. Comparatively, 5.8% of Estrella Immunopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Artiva Biotherapeutics has a beta of 2.38, suggesting that its share price is 138% more volatile than the broader market. Comparatively, Estrella Immunopharma has a beta of 0.85, suggesting that its share price is 15% less volatile than the broader market.

In the previous week, Artiva Biotherapeutics had 1 more articles in the media than Estrella Immunopharma. MarketBeat recorded 2 mentions for Artiva Biotherapeutics and 1 mentions for Estrella Immunopharma. Artiva Biotherapeutics' average media sentiment score of 0.97 beat Estrella Immunopharma's score of 0.87 indicating that Artiva Biotherapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Artiva Biotherapeutics	Positive
Estrella Immunopharma	Positive

Estrella Immunopharma's return on equity of 0.00% beat Artiva Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artiva Biotherapeutics	N/A	-73.15%	-62.74%
Estrella Immunopharma	N/A	N/A	-397.36%

Estrella Immunopharma has lower revenue, but higher earnings than Artiva Biotherapeutics. Estrella Immunopharma is trading at a lower price-to-earnings ratio than Artiva Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artiva Biotherapeutics	$250K	730.82	-$83.86M	-$3.54	N/A
Estrella Immunopharma	N/A	N/A	-$13.06M	-$0.34	N/A

Summary

Artiva Biotherapeutics beats Estrella Immunopharma on 10 of the 15 factors compared between the two stocks.

How does Estrella Immunopharma compare to Cartesian Therapeutics?

Cartesian Therapeutics (NASDAQ:RNAC) and Estrella Immunopharma (NASDAQ:ESLA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, media sentiment, valuation and earnings.

Estrella Immunopharma has lower revenue, but higher earnings than Cartesian Therapeutics. Estrella Immunopharma is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cartesian Therapeutics	$2.80M	69.10	-$130.30M	-$5.90	N/A
Estrella Immunopharma	N/A	N/A	-$13.06M	-$0.34	N/A

In the previous week, Cartesian Therapeutics and Cartesian Therapeutics both had 1 articles in the media. Estrella Immunopharma's average media sentiment score of 0.87 beat Cartesian Therapeutics' score of 0.62 indicating that Estrella Immunopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cartesian Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Estrella Immunopharma	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Cartesian Therapeutics has a beta of 0.66, meaning that its stock price is 34% less volatile than the broader market. Comparatively, Estrella Immunopharma has a beta of 0.85, meaning that its stock price is 15% less volatile than the broader market.

Estrella Immunopharma has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -8,550.65%.

Company	Net Margins	Return on Equity	Return on Assets
Cartesian Therapeutics	-8,550.65%	N/A	-28.25%
Estrella Immunopharma	N/A	N/A	-397.36%

87.0% of Cartesian Therapeutics shares are held by institutional investors. Comparatively, 0.4% of Estrella Immunopharma shares are held by institutional investors. 37.2% of Cartesian Therapeutics shares are held by company insiders. Comparatively, 5.8% of Estrella Immunopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Cartesian Therapeutics currently has a consensus price target of $32.60, suggesting a potential upside of 395.06%. Estrella Immunopharma has a consensus price target of $8.00, suggesting a potential upside of 595.65%. Given Estrella Immunopharma's higher possible upside, analysts plainly believe Estrella Immunopharma is more favorable than Cartesian Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cartesian Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Estrella Immunopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Cartesian Therapeutics beats Estrella Immunopharma on 7 of the 13 factors compared between the two stocks.

How does Estrella Immunopharma compare to Maxpro Capital Acquisition?

Estrella Immunopharma (NASDAQ:ESLA) and Maxpro Capital Acquisition (NASDAQ:JMAC) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, earnings and media sentiment.

0.4% of Estrella Immunopharma shares are owned by institutional investors. Comparatively, 73.2% of Maxpro Capital Acquisition shares are owned by institutional investors. 5.8% of Estrella Immunopharma shares are owned by company insiders. Comparatively, 19.3% of Maxpro Capital Acquisition shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Estrella Immunopharma has a beta of 0.85, indicating that its share price is 15% less volatile than the broader market. Comparatively, Maxpro Capital Acquisition has a beta of 0.01, indicating that its share price is 99% less volatile than the broader market.

In the previous week, Estrella Immunopharma had 1 more articles in the media than Maxpro Capital Acquisition. MarketBeat recorded 1 mentions for Estrella Immunopharma and 0 mentions for Maxpro Capital Acquisition. Estrella Immunopharma's average media sentiment score of 0.87 beat Maxpro Capital Acquisition's score of 0.00 indicating that Estrella Immunopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Estrella Immunopharma	Positive
Maxpro Capital Acquisition	Neutral

Estrella Immunopharma presently has a consensus target price of $8.00, suggesting a potential upside of 595.65%. Given Estrella Immunopharma's stronger consensus rating and higher probable upside, research analysts plainly believe Estrella Immunopharma is more favorable than Maxpro Capital Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Estrella Immunopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Maxpro Capital Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Net Margins	Return on Equity	Return on Assets
Estrella Immunopharma	N/A	N/A	-397.36%
Maxpro Capital Acquisition	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Estrella Immunopharma	N/A	N/A	-$13.06M	-$0.34	N/A
Maxpro Capital Acquisition	N/A	N/A	N/A	N/A	N/A

Summary

Estrella Immunopharma beats Maxpro Capital Acquisition on 6 of the 9 factors compared between the two stocks.

Get Estrella Immunopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ESLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ESLA vs. The Competition

Export

Metric	Estrella Immunopharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$49.48M	$3.33B	$6.42B	$12.48B
Dividend Yield	N/A	2.37%	2.69%	5.22%
P/E Ratio	-3.38	18.86	23.85	24.39
Price / Sales	N/A	319.25	520.29	116.29
Price / Cash	N/A	110.40	41.27	57.13
Price / Book	-4.26	6.82	10.04	6.74
Net Income	-$13.06M	$24.09M	$3.56B	$337.03M
7 Day Performance	0.88%	-2.69%	-1.09%	0.13%
1 Month Performance	N/A	N/A	N/A	-1.67%
1 Year Performance	16.16%	48.33%	28.56%	34.29%

Estrella Immunopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ESLA Estrella Immunopharma	2.7632 of 5 stars	$1.15 +10.6%	$8.00 +595.7%	+27.7%	$49.48M	N/A	N/A	N/A	News Coverage Short Interest Decrease
DTIL Precision BioSciences	2.2177 of 5 stars	$7.59 +0.1%	$36.33 +378.7%	+17.3%	$195.58M	$34.26M	N/A	200	Gap Up High Trading Volume
TLSA Tiziana Life Sciences	0.6334 of 5 stars	$1.47 -2.6%	N/A	-16.9%	$192.16M	N/A	N/A	8
ARTV Artiva Biotherapeutics	4.2474 of 5 stars	$7.63 -0.5%	$39.00 +411.1%	+257.1%	$189.58M	$250K	N/A	81	Short Interest Increase
RNAC Cartesian Therapeutics	2.5615 of 5 stars	$6.93 +7.4%	$32.60 +370.4%	-36.8%	$189.51M	$2.80M	N/A	64

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ESLA) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Estrella Immunopharma (ESLA) Competitors

ESLA vs. DTIL, TLSA, ARTV, RNAC, and JMAC

How does Estrella Immunopharma compare to Precision BioSciences?

Summary

How does Estrella Immunopharma compare to Tiziana Life Sciences?

Summary

How does Estrella Immunopharma compare to Artiva Biotherapeutics?

Summary

How does Estrella Immunopharma compare to Cartesian Therapeutics?

Summary

How does Estrella Immunopharma compare to Maxpro Capital Acquisition?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ESLA vs. The Competition

Estrella Immunopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Estrella Immunopharma (ESLA) Competitors

ESLA vs. DTIL, TLSA, ARTV, RNAC, and JMAC

How does Estrella Immunopharma compare to Precision BioSciences?

Which has higher valuation & earnings, DTIL or ESLA?

Which has more risk and volatility, DTIL or ESLA?

Do institutionals and insiders hold more shares of DTIL or ESLA?

Do analysts rate DTIL or ESLA?

Does the media prefer DTIL or ESLA?

Is DTIL or ESLA more profitable?

Summary

How does Estrella Immunopharma compare to Tiziana Life Sciences?

Do analysts rate ESLA or TLSA?

Which has more risk and volatility, ESLA or TLSA?

Do institutionals and insiders believe in ESLA or TLSA?

Does the media refer more to ESLA or TLSA?

Is ESLA or TLSA more profitable?

Which has preferable earnings and valuation, ESLA or TLSA?

Summary

How does Estrella Immunopharma compare to Artiva Biotherapeutics?

Do analysts recommend ARTV or ESLA?

Do institutionals & insiders believe in ARTV or ESLA?

Which has more risk and volatility, ARTV or ESLA?

Does the media prefer ARTV or ESLA?

Is ARTV or ESLA more profitable?

Which has higher earnings & valuation, ARTV or ESLA?

Summary

How does Estrella Immunopharma compare to Cartesian Therapeutics?

Which has preferable earnings and valuation, RNAC or ESLA?

Does the media prefer RNAC or ESLA?

Which has more volatility and risk, RNAC or ESLA?

Is RNAC or ESLA more profitable?

Do institutionals and insiders have more ownership in RNAC or ESLA?

Do analysts rate RNAC or ESLA?

Summary

How does Estrella Immunopharma compare to Maxpro Capital Acquisition?

Do insiders and institutionals hold more shares of ESLA or JMAC?

Which has more risk & volatility, ESLA or JMAC?

Does the media refer more to ESLA or JMAC?

Do analysts rate ESLA or JMAC?

Is ESLA or JMAC more profitable?

Which has better earnings & valuation, ESLA or JMAC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ESLA vs. The Competition

Estrella Immunopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools